This drug maker’s kidney disease treatment scores $50M payday

FibroGen Inc. will receive $50 million from partner AstraZeneca after federal regulators accepted the San Francisco company's application to approve a drug for treating anemia in chronic kidney disease patients. Acceptance of FibroGen's new drug application for the drug, called roxadustat, by the Food and Drug Administration means AstraZeneca plc (NYSE: AZN) must pay $50 million to FibroGen, the company said in a Securities and Exchange Commission filing Tuesday. Roxadustat now is on the road for?

Click to view original post